04 March 2011, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:
ATSMY) notifies the market that the Company's issued share capital consists of
632,518,777 ordinary shares with voting rights. Antisoma does not hold any
ordinary shares in Treasury.
Therefore, the total number of voting rights in Antisoma is 632,518,777.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, Antisoma under the FSA's
Disclosure and Transparency Rules.
Marketing and Communications Manager
+44 (0)20 3249 2100
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the UK and the US. Please visitwww.antisoma.com for further information about
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Antisoma plc via Thomson Reuters ONE